Novartis Company Insiders
NVS Stock | USD 94.36 1.79 1.93% |
Novartis employs about 76.1 K people. The company is managed by 70 executives with a total tenure of roughly 575 years, averaging almost 8.0 years of service per executive, having 1086.53 employees per reported executive. Breaking down Novartis' management performance can provide insight into the firm performance.
Chris Ilsley CEO President CEO |
Elizabeth Barrett CEO CEO, Novartis Oncology |
Novartis |
Novartis' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Novartis' future performance. Based on our forecasts, it is anticipated that Novartis will maintain a workforce of slightly above 76060 employees by May 2024.Novartis' latest congressional trading
Congressional trading in companies like Novartis AG ADR, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Novartis by those in governmental positions are based on the same information available to the general public.
2023-09-20 | Senator Sheldon Whitehouse | Acquired $15K to $50K | Verify | ||
2023-07-10 | Representative Daniel Goldman | Disposed $50K to $100K | Verify | ||
2023-04-26 | Senator Thomas R. Carper | Acquired Under $15K | Verify | ||
2023-01-31 | Representative Kevin Hern | Disposed Under $15K | Verify | ||
2022-03-16 | Representative John Rutherford | Disposed Under $15K | Verify | ||
2022-02-28 | Representative Donald S. Beyer, Jr. | Disposed Under $15K | Verify | ||
2021-12-15 | Senator Shelley Moore Capito | Acquired Under $15K | Verify | ||
2020-11-23 | Representative Alan S. Lowenthal | Disposed $15K to $50K | Verify | ||
2020-03-18 | Representative Greg Gianforte | Acquired Under $15K | Verify | ||
2020-02-20 | Representative Mikie Sherrill | Disposed Under $15K | Verify | ||
2019-04-05 | Senator William Cassidy | Acquired Under $15K | Verify | ||
2018-12-07 | Senator Bill Cassidy | Acquired Under $15K | Verify | ||
2018-04-24 | Senator Shelley M Capito | Acquired Under $15K | Verify | ||
2017-11-10 | Senator Angus S. King, Jr. | Acquired Under $15K | Verify |
Novartis Management Team Effectiveness
The company has Return on Asset of 0.0727 % which means that on every $100 spent on assets, it made $0.0727 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1615 %, implying that it generated $0.1615 on every 100 dollars invested. Novartis' management efficiency ratios could be used to measure how well Novartis manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Novartis' Return On Tangible Assets are comparatively stable compared to the past year. Return On Capital Employed is likely to gain to 0.14 in 2024, whereas Return On Assets are likely to drop 0.11 in 2024. At this time, Novartis' Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 73.2 B in 2024, whereas Total Current Assets are likely to drop slightly above 29.9 B in 2024.Net Income Applicable To Common Shares is likely to gain to about 9.8 B in 2024, whereas Common Stock Shares Outstanding is likely to drop slightly above 1.9 B in 2024.
Novartis Workforce Comparison
Novartis AG ADR is considered to be number one stock in number of employees category among related companies. The total workforce of Health Care industry is now estimated at about 80,721. Novartis totals roughly 76,057 in number of employees claiming about 94% of equities under Health Care industry.
Novartis Profit Margins
The company has Net Profit Margin of 0.32 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.25 %, which entails that for every 100 dollars of revenue, it generated $0.25 of operating income.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.78 | 0.7327 |
|
| |||||
Net Profit Margin | 0.17 | 0.3183 |
|
| |||||
Operating Profit Margin | 0.18 | 0.2094 |
|
| |||||
Pretax Profit Margin | 0.25 | 0.1955 |
|
| |||||
Return On Assets | 0.11 | 0.1486 |
|
| |||||
Return On Equity | 0.33 | 0.3182 |
|
|
Novartis AG ADR Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Novartis AG ADR Price Series Summation is a cross summation of Novartis price series and its benchmark/peer.
Novartis Notable Stakeholders
A Novartis stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Novartis often face trade-offs trying to please all of them. Novartis' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Novartis' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Chris Ilsley | President CEO | Profile | |
Richard Saynor | Chief Executive Officer of Sandoz, Member of the Executive Committee | Profile | |
Elizabeth Barrett | CEO, Novartis Oncology | Profile | |
Francesco Balestrieri | Chief Executive Officer of Sandoz, Member of the Executive Committee | Profile | |
Paul Hudson | Chief Executive Officer of Novartis Pharmaceuticals, Member of the Executive Committee | Profile | |
Bruno Strigini | CEO of Novartis Oncology, Member of the Executive Committee | Profile | |
Michael Ball | CEO of Alcon, Member of the Executive Committee | Profile | |
Joseph Jimenez | CEO, Member of the Executive Committee | Profile | |
Daniel Vasella | Honorary Chairman of the Board | Profile | |
Joerg Reinhardt | Independent Non-Executive Chairman of the Board | Profile | |
Enrico Vanni | Lead Independent Non-Executive Vice Chairman of the Board | Profile | |
Alex Krauer | Honorary Chairman of the Board | Profile | |
Ulrich Lehner | Vice Chairman of the Board of Directors, Non-Executive Director | Profile | |
Fiona Marshall | President Research | Profile | |
Mark Fishman | Member of the Executive Committee and President of Novartis Institute for BioMedical Research (NIBR) | Profile | |
Shreeram MD | President Officer | Profile | |
MarieFrance Tschudin | President, Innovative Medicines International and Chief Commercial Officer, Member of the Executive Board | Profile | |
Susanne Schaffert | President of Novartis Oncology, Member of the Executive Committee | Profile | |
Patrick MD | President International | Profile | |
Andre Wyss | Member of the Executive Committee, Novartis Business Services and Country President for Switzerland | Profile | |
James Bradner | President of the Novartis Institutes for BioMedical Research (NIBR), Member of the Executive Committee | Profile | |
Harry Kirsch | Chief Financial Officer, Member of the Executive Committee | Profile | |
Ton Buechner | Non-Executive Independent Director | Profile | |
Pierre Landolt | Member of the Board of Directors | Profile | |
Elizabeth Doherty | Non-Executive Independent Director | Profile | |
Srikant Datar | Non-Executive Independent Director | Profile | |
Simon Moroney | Non-Executive Independent Director | Profile | |
Dimitri Azar | Non-Executive Independent Director | Profile | |
Frans Houten | Non-Executive Independent Director | Profile | |
Nancy Andrews | Non-Executive Independent Director | Profile | |
Andreas Planta | Non-Executive Independent Director | Profile | |
Ann Fudge | Non-Executive Independent Director | Profile | |
Bridgette Heller | Non-Executive Independent Director | Profile | |
Charlotte Wieser | Corporate Secretary | Profile | |
Robert PharmD | Chief Officer | Profile | |
Verena Briner | Non-Executive Independent Member of the Board | Profile | |
Karen Hale | Chief Legal Officer, Member of the Executive Board | Profile | |
Steven Baert | Chief People & Organization Officer, Member of the Executive Committee | Profile | |
Richard Francis | Member of the Executive Committee and Division Head, Sandoz | Profile | |
Erwin Vanhaecke | Head Novartis Group Quality | Profile | |
Victor Bulto | President Innovative Medicines US, Member of the Executive Board | Profile | |
Charlotte PamerWieser | Corporate Secretary | Profile | |
Shannon Klinger | Chief Risk and Compliance Officer, Group General Counsel | Profile | |
Samir Shah | Global Head Investor Relations | Profile | |
David Epstein | Member of the Executive Committee, Division Head, Pharmaceuticals | Profile | |
Samir MD | Global Relations | Profile | |
Steffen Lang | Global Head of Novartis Technical Operations, Member of the Executive Committee | Profile | |
Paul Penepent | Head Accounting | Profile | |
Brian McNamara | Member of the Management Board, Division Head, Novartis OTC | Profile | |
Andrews C | Non-Executive Independent Director | Profile | |
Michele Galen | Head Communications | Profile | |
Charles Sawyers | Non-Executive Independent Member of the Board | Profile | |
Etienne Jousseaume | Cell Access | Profile | |
John Tsai | Head of Global Drug Development and Chief Medical Officer, Member of the Executive Committee | Profile | |
Bertrand Bodson | Chief Digital Officer, Member of the Executive Committee | Profile | |
Robert Weltevreden | Head of Customer and Technology Solutions, Member of the Executive Committee | Profile | |
Vasant Narasimhan | Global Head of Drug Development and Chief Medical Officer for Novartis, Member of the Executive Committee | Profile | |
Jeffrey George | Member of the Executive Committee and Division Head, Sandoz | Profile | |
Patrice Bula | Non-Executive Independent Director | Profile | |
Linda MD | Global Development | Profile | |
Peter Kornicker | Chief Compliance Officer | Profile | |
William Winters | Non-Executive Independent Member of the Board | Profile | |
Robert Kowalski | Chief People and Organization Officer | Profile | |
George Gunn | Member of the Executive Committee, Division Head, Novartis Animal Health of Head, Corporate Responsibility | Profile | |
Paul Arkel | Head of Corporate Strategy and External Affairs | Profile | |
Klaus Moosmayer | Chief Ethics, Risk and Compliance Officer, Member of the Executive Committee | Profile | |
Aharon Gal | Chief Officer | Profile | |
Vasant MD | Chief Officer | Profile | |
Felix Ehrat | General Counsel and General Counsel of Novartis International Ag | Profile | |
Andrin Oswald | Member of the Executive Committee, Division Head, Vaccines and Diagnostics | Profile |
About Novartis Management Performance
The success or failure of an entity such as Novartis AG ADR often depends on how effective the management is. Novartis management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Novartis management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Novartis management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.30 | 0.31 | |
Return On Capital Employed | 0.13 | 0.14 | |
Return On Assets | 0.15 | 0.11 | |
Return On Equity | 0.32 | 0.33 |
The data published in Novartis' official financial statements usually reflect Novartis' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Novartis AG ADR. For example, before you start analyzing numbers published by Novartis accountants, it's critical to develop an understanding of what Novartis' liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of Novartis' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Novartis' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Novartis' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Novartis AG ADR. Please utilize our Beneish M Score to check the likelihood of Novartis' management manipulating its earnings.
Novartis Workforce Analysis
Traditionally, organizations such as Novartis use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Novartis within its industry.Novartis Manpower Efficiency
Return on Novartis Manpower
Revenue Per Employee | 613.5K | |
Revenue Per Executive | 666.6M | |
Net Income Per Employee | 112.7K | |
Net Income Per Executive | 122.5M | |
Working Capital Per Employee | 53.8K | |
Working Capital Per Executive | 58.4M |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novartis AG ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Complementary Tools for Novartis Stock analysis
When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |
Is Novartis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novartis. If investors know Novartis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novartis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 4.987 | Dividend Share 3.919 | Earnings Share 4.1 | Revenue Per Share 22.467 | Quarterly Revenue Growth 0.074 |
The market value of Novartis AG ADR is measured differently than its book value, which is the value of Novartis that is recorded on the company's balance sheet. Investors also form their own opinion of Novartis' value that differs from its market value or its book value, called intrinsic value, which is Novartis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novartis' market value can be influenced by many factors that don't directly affect Novartis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novartis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Novartis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novartis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.